申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20180370956A1
公开(公告)日:2018-12-27
Compounds having the following formula:
or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R
2
is a monocyclic heteroaryl group, and R
1
, R
3
, R
4
, R
5
and R
6
are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.